These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 18474249)

  • 1. FDA approves Cimzia to treat Crohn's disease.
    Lang L
    Gastroenterology; 2008 Jun; 134(7):1819. PubMed ID: 18474249
    [No Abstract]   [Full Text] [Related]  

  • 2. Certolizumab (Cimzia) for Crohn's disease.
    Med Lett Drugs Ther; 2008 Oct; 50(1297):81-2. PubMed ID: 18927521
    [No Abstract]   [Full Text] [Related]  

  • 3. TNF inhibitors for Crohn's disease: when, which, and for how long.
    Med Lett Drugs Ther; 2013 Dec; 55(1432):102-3. PubMed ID: 24419244
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug approvals: '08 in review. Certolizumab pegol (Cimzia).
    Laustsen G; Carrillo F; Johnson J; Smith C
    Nurse Pract; 2009 Feb; 34(2):26-7. PubMed ID: 19155878
    [No Abstract]   [Full Text] [Related]  

  • 5. The classics in perspective.
    Panés J; Ghosh S
    Gut; 2007 Sep; 56(9):1184-6. PubMed ID: 17698863
    [No Abstract]   [Full Text] [Related]  

  • 6. Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease.
    Smith LS; Nelson M; Dolder CR
    Ann Pharmacother; 2010 Feb; 44(2):333-42. PubMed ID: 20118143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health outcomes and cost-effectiveness of certolizumab pegol in the treatment of Crohn's disease.
    Augustine JM; Lee JK; Armstrong EP
    Expert Rev Pharmacoecon Outcomes Res; 2014 Oct; 14(5):599-609. PubMed ID: 25209304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to manage difficult Crohn's disease: optimum delivery of anti-TNFs.
    Krygier DS; Ko HH; Bressler B
    Expert Rev Gastroenterol Hepatol; 2009 Aug; 3(4):407-15. PubMed ID: 19673627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remicade approved for children with Crohn's disease.
    FDA Consum; 2006; 40(4):6. PubMed ID: 17245830
    [No Abstract]   [Full Text] [Related]  

  • 10. [Inflammatory bowel diseases--new therapeutic options].
    Herrlinger K; Stange EF
    Med Klin (Munich); 2008 Feb; 103(2):90-101; quiz 102-3. PubMed ID: 18270665
    [No Abstract]   [Full Text] [Related]  

  • 11. [Certolizumab pegol--new possibilities in the treatment of Crohn's disease].
    Lazebnik LB; Kniazev OV
    Eksp Klin Gastroenterol; 2012; (3):100-5. PubMed ID: 22830233
    [No Abstract]   [Full Text] [Related]  

  • 12. Cimzia's setback paves way for other TNF inhibitors in Crohn's disease.
    Sheridan C
    Nat Biotechnol; 2007 May; 25(5):487-8. PubMed ID: 17483820
    [No Abstract]   [Full Text] [Related]  

  • 13. The safety of biologic agents in the treatment of inflammatory bowel disease.
    Shepela C
    Minn Med; 2008 Jun; 91(6):42-5. PubMed ID: 18616021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.
    Prescrire Int; 2009 Jun; 18(101):108-10. PubMed ID: 19637418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Certolizumab pegol for the management of Crohn's disease in adults.
    Rivkin A
    Clin Ther; 2009 Jun; 31(6):1158-76. PubMed ID: 19695385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintenance therapy with certolizumab pegol for Crohn's disease.
    Schreiber S; Khaliq-Kareemi M; Lawrance IC; Thomsen OØ; Hanauer SB; McColm J; Bloomfield R; Sandborn WJ;
    N Engl J Med; 2007 Jul; 357(3):239-50. PubMed ID: 17634459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn disease. A survey of a Cochrane review].
    Al-Subeihe I; Nielsen OH
    Ugeskr Laeger; 2008 Dec; 170(50):4130-4. PubMed ID: 19091193
    [No Abstract]   [Full Text] [Related]  

  • 18. Oral lichen planus after certolizumab pegol treatment in a patient with Crohn's disease.
    Mocciaro F; Orlando A; Renna S; Rizzuto MR; Cottone M
    J Crohns Colitis; 2011 Apr; 5(2):173-4. PubMed ID: 21453892
    [No Abstract]   [Full Text] [Related]  

  • 19. Meningococcal meningoencephalitis after certolizumab pegol treatment in a patient with Crohn's disease.
    Majumder S; Kumar A
    J Crohns Colitis; 2013 Feb; 7(1):e19. PubMed ID: 22742971
    [No Abstract]   [Full Text] [Related]  

  • 20. Certolizumab pegol for the treatment of Crohn's disease.
    Sandborn WJ; Feagan BG; Stoinov S; Honiball PJ; Rutgeerts P; Mason D; Bloomfield R; Schreiber S;
    N Engl J Med; 2007 Jul; 357(3):228-38. PubMed ID: 17634458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.